Literature DB >> 17122639

Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma.

Vahid Haghpanah1, Peiman Shooshtarizadeh, Ramin Heshmat, Bagher Larijani, Seyed Mohamad Tavangar.   

Abstract

Survivin is one of the 8 members of human inhibitor of apoptosis , which is differentially expressed in cancerous/transformed cells versus normal differentiated tissues. This retrospective study of thyroid histologic samples aimed to assess the clinical usefulness of survivin immunostaining for discrimination between follicular adenoma and carcinoma of thyroid. Immunohistochemical staining for survivin was performed on 41 lesions from patients who had undergone surgery for either follicular adenoma or carcinoma of thyroid. Survivin expression was significantly (P < 0.005) higher in the cases that received a diagnosis of carcinoma in comparison with follicular adenomas cases. Odds ratio of follicular carcinoma for survivin expression was 21.375 (95% CI: 3.283 to 139.177). Our results showed potential value of survivin in discrimination between follicular thyroid adenoma and follicular thyroid carcinoma. We conclude that survivin is a potential candidate for further investigation in the proper histologic diagnosis of thyroid cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17122639     DOI: 10.1097/01.pai.0000213100.88074.b8

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  16 in total

1.  Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.

Authors:  Javad Mohammadi-asl; Bagher Larijani; Zhamak Khorgami; Seyed Mohammad Tavangar; Vahid Haghpanah; Majid Kheirollahi; Parvin Mehdipour
Journal:  Med Oncol       Date:  2010-06-10       Impact factor: 3.064

2.  Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma.

Authors:  Hai-Yan Zhang; Xin Meng; Zhen-Xian Du; Chang-Qing Fang; Guo-Liang Liu; Hua-Qin Wang; Wei-Wei Deng
Journal:  Clin Exp Med       Date:  2009-02-10       Impact factor: 3.984

3.  The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 δ in Follicular Thyroid Carcinoma.

Authors:  Min Hye Jang; Kyeong Cheon Jung; Hye Sook Min
Journal:  J Pathol Transl Med       Date:  2015-03-12

4.  Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer.

Authors:  Fatemeh Khatami; Bagher Larijani; Ramin Heshmat; Abbasali Keshtkar; Mahsa Mohammadamoli; Ladan Teimoori-Toolabi; Shirzad Nasiri; Seyed Mohammad Tavangar
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

5.  Genetic and Epigenetic of Medullary Thyroid Cancer

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran Biomed J       Date:  2017-11-11

Review 6.  Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran J Pathol       Date:  2017-07-01

7.  Clear Cell Sarcoma: A Case Report and Review of Literature.

Authors:  Alireza Abdollahi; Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-01-01

Review 8.  Oncometabolites as biomarkers in thyroid cancer: a systematic review.

Authors:  Fatemeh Khatami; Moloud Payab; Masoumeh Sarvari; Kambiz Gilany; Bagher Larijani; Babak Arjmand; Seyed Mohammad Tavangar
Journal:  Cancer Manag Res       Date:  2019-02-25       Impact factor: 3.989

Review 9.  Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Biomark Insights       Date:  2018-07-02

Review 10.  Liquid Biopsy in Thyroid Cancer: New Insight.

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.